Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Inclusion Criteria: * Documented diagnosis of CD at least 3 months prior to enrollment * Taking any brand or dosage of an oral aminosalicylate for at least 6 months * Subject-confirmed compliance with current aminosalicylate therapy (taking at least 75% of prescribed doses) * CD currently in clinical remission * Able to participate fully in all aspects of the clinical trial * Written informed consent obtained and documented Exclusion Criteria: * A current diagnosis of UC, indeterminate colitis, microscopic colitis, or diverticular disease-associated colitis * A diagnosis of short-bowel syndrome * Active perianal disease * Active fistulizing disease * A flare of CD within 3 months prior to enrollment requiring initiation/escalation of medical therapy or surgery * Use of systemic corticosteroids for CD (2 continuous weeks or more) within 3 months prior to enrollment * Any major resective bowel surgery for CD (ileal resection, ileocecal resection, proctocolectomy, colectomy, enterectomy, ostomy formation and repair, anastomosis/reanastomosis) within 6 months prior to enrollment * Unwillingness to stop taking aminosalicylates for the duration of the trial * Untreated bile salt malabsorption that, in the opinion of the investigator, may interfere with accurate study HBI assessment * Serious underlying disease other than CD that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study * History of active alcohol or drug abuse that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures * Currently participating in another interventional trial, or previous participation within the last 3 months